Phase 3 N=330 Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
Acanthamoeba Keratitis · Fungal Keratitis
Primary: Best Spectacle-Corrected Visual Acuity — 0.614; 0.666 logMAR
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=527 Zoster Eye Disease Study
Herpes Zoster Ophthalmicus
Primary: Number of Participants With the First Occurrence of New or Worsening Stromal Keratitis Without Ulceration (SK), Endothelial Keratitis (EK), Iritis (IR), Dendriform…
Phase 2 N=108 REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients
Neurotrophic Keratitis
Primary: Corneal Healing — 4; 2; 1; 2 Participants
Phase 2 N=174 Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.
Neurotrophic Keratitis · Keratitis · Corneal Ulcer
Primary: Percentage of Patients Achieving Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer — 55; 58; 20; 45 percentage of subjects — p=<0.001
Phase 2 N=131 Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects
Neurotrophic Keratitis
Primary: Efficacy as Assessed by Complete Corneal Healing — 21; 16 Participants
Phase 3 N=350 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)
Dry Eye Disease With Severe Keratitis
Primary: The Correlation Between Mean Change From Baseline in Corneal Fluorescein Staining (CFS) Score and Symptom Assessment iN Dry Eye (SANDE) Symptoms Score at Each Visit…
Phase 4 N=17 Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis
Keratitis
Primary: Correlation Between the Change From Baseline in VMR Measured With FVA System at Month 3 and the Change From Baseline in the CFS at Month 3. — -0.7028 Spearman's…
Phase 3 N=70 Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers
Corneal Ulcer · Fungal Keratitis
Primary: Culture Positivity at Day 3 Using Potassium Hydroxide (KOH) Wet Mount to Test for Fungus — 14; 11 Participants — p=0.26
Phase 4 N=37 Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis
Neurotrophic Keratitis
Primary: Corneal Epithelial Healing — 5; 28 Participants
N/A N=15 Mucinex® for Treatment of Filamentary Keratitis
Filamentary Keratitis
Primary: Change in Number of Corneal Filaments — 5.8; 2.1 corneal filaments — p=<0.04
Phase 4 N=36 Impact of Acthar on Everyday Life of Participants With Severe Keratitis
Keratitis
Primary: Number of Participants Who Improved on the Impact of Dry Eye on Everyday Life (IDEEL) Scale [Using the Symptom Bother Module at Week 12] — 17 Participants
Phase 3 N=134 Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis
Acanthamoeba Keratitis
Primary: Clinical Resolution Rate — 84.8; 88.5 percentage of participants
Phase 2 N=48 Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK
Neurotrophic Keratitis
Primary: Complete Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer Defined by Central Reviewer — 70; 29; 30; 71 percentage of participants — p==0.006
N/A N=24 DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
Neurotrophic Keratitis
Primary: Number/Percentage of Patients Who Achieved Corneal Epithelial Healing at NGF0120 Week 8 (EoT NGF0120=Baseline NGF0122) and Remained Healed at Month 24 and Month 30 of…
Phase 3 N=152 Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer
Keratitis · Corneal Ulcer
Primary: Number of Participants With a Reduction in Neurotrophic the Keratitis/Ulcer Area on Day28 — 37; 44 Participants